BBI Solutions has launched Morffi, a conjugate blocking technology that enhances signal intensity and improves the sensitivity of lateral flow immunoassays.

 

The proprietary Morffi technology overcomes cross-reaction issues due to its size in comparison to BSA, and it improves the availability of analyte-specific binding partners on the surface of the reporter label, increasing the signal intensity and sensitivity of the assay. Morffi has been successfully tested with over 30 conjugates to date, clearly demonstrating its suitability for a range of LFIs.